Cargando…
Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC
BACKGROUNDS: p53 is a tumor suppressor that prevents cancer onset and progression, and mutations in the p53 gene cause loss of the tumor suppressor function of the protein. The mutant p53 protein in tumor cells can form aggregates which contribute to the dominant-negative effect over the wild-type p...
Autores principales: | Zhang, Yaqun, Xu, Lingfan, Chang, Yan, Li, YanJing, Butler, William, Jin, Er, Wang, Aifen, Tao, Yulei, Chen, Xufeng, Liang, Chaozhao, Huang, Jiaoti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031025/ https://www.ncbi.nlm.nih.gov/pubmed/31471556 http://dx.doi.org/10.1038/s41391-019-0172-z |
Ejemplares similares
-
Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
por: Neal, Adam, et al.
Publicado: (2021) -
Correction to: N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ ATM pathway
por: Yin, Yu, et al.
Publicado: (2019) -
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway
por: Yin, Yu, et al.
Publicado: (2019) -
Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells
por: Lei, Kefeng, et al.
Publicado: (2018) -
Serum lipid profiles and aggressive prostate cancer
por: Li, Yanjing, et al.
Publicado: (2015)